Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R5XK
|
|||
| Former ID |
DNC012014
|
|||
| Drug Name |
ONO-1714
|
|||
| Synonyms |
CHEMBL1800346; CHEMBL105792; SCHEMBL2717045; BDBM50386178
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Sepsis [ICD-11: 1G40-1G41; ICD-10: R57.2; ICD-9: 785.52] | Discontinued in Phase 1 | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C7H12Cl2N2
|
|||
| Canonical SMILES |
CC1CC(=NC2C1C2Cl)N.Cl
|
|||
| InChI |
1S/C7H11ClN2.ClH/c1-3-2-4(9)10-7-5(3)6(7)8;/h3,5-7H,2H2,1H3,(H2,9,10);1H/t3-,5-,6+,7-;/m0./s1
|
|||
| InChIKey |
IZIZKGZAEABSET-IEUZAGAGSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nitric-oxide synthase inducible (NOS2) | Target Info | Modulator | [2], [3] |
| BioCyc | Citrulline-nitric oxide cycle | |||
| KEGG Pathway | Arginine biosynthesis | |||
| Arginine and proline metabolism | ||||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| HIF-1 signaling pathway | ||||
| Peroxisome | ||||
| Salmonella infection | ||||
| Pertussis | ||||
| Leishmaniasis | ||||
| Chagas disease (American trypanosomiasis) | ||||
| Toxoplasmosis | ||||
| Amoebiasis | ||||
| Tuberculosis | ||||
| Pathways in cancer | ||||
| Small cell lung cancer | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | IL12-mediated signaling events | |||
| Alpha9 beta1 integrin signaling events | ||||
| ATF-2 transcription factor network | ||||
| IL23-mediated signaling events | ||||
| Signaling mediated by p38-alpha and p38-beta | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | ROS production in response to bacteria | |||
| Nitric oxide stimulates guanylate cyclase | ||||
| WikiPathways | Type II interferon signaling (IFNG) | |||
| Spinal Cord Injury | ||||
| AGE/RAGE pathway | ||||
| Effects of Nitric Oxide | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013758) | |||
| REF 2 | ONO-1714, a new inducible nitric oxide synthase inhibitor, attenuates diaphragmatic dysfunction associated with cerulein-induced pancreatitis in rats. Crit Care Med. 2001 Jun;29(6):1215-21. | |||
| REF 3 | The potent inducible nitric oxide synthase inhibitor ONO-1714 inhibits neuronal NOS and exerts antinociception in rats. Neurosci Lett. 2004 Jul 22;365(2):111-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.